|
Name |
Chaetoviridin G
|
Molecular Formula | C23H25ClO5 | |
IUPAC Name* |
(6aS,9R,9aS)-5-chloro-6a-methyl-9-[(E)-2-methylbut-2-enoyl]-3-[(E,3S)-3-methylpent-1-enyl]-9,9a-dihydrofuro[2,3-h]isochromene-6,8-dione
|
|
SMILES |
CC[C@H](C)/C=C/C1=CC2=C(C(=O)[C@@]3([C@H](C2=CO1)[C@@H](C(=O)O3)C(=O)/C(=C/C)/C)C)Cl
|
|
InChI |
InChI=1S/C23H25ClO5/c1-6-12(3)8-9-14-10-15-16(11-28-14)18-17(20(25)13(4)7-2)22(27)29-23(18,5)21(26)19(15)24/h7-12,17-18H,6H2,1-5H3/b9-8+,13-7+/t12-,17+,18+,23-/m0/s1
|
|
InChIKey |
GFTHCZMPYKVNIC-GETGECRZSA-N
|
|
Synonyms |
Chaetoviridin G; Chaetomugilin O; CHEBI:67619; CHEMBL1802158; Q27136086; (6aS,9R,9aS)-5-chloro-6a-methyl-9-[(2E)-2-methylbut-2-enoyl]-3-[(1E,3S)-3-methylpent-1-en-1-yl]-9,9a-dihydro-6H-furo[2,3-h]isochromene-6,8(6aH)-dione
|
|
CAS | NA | |
PubChem CID | 44250068 | |
ChEMBL ID | CHEMBL1802158 |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 416.9 | ALogp: | 4.3 |
HBD: | 0 | HBA: | 5 |
Rotatable Bonds: | 5 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 69.7 | Aromatic Rings: | 3 |
Heavy Atoms: | 29 | QED Weighted: | 0.357 |
Caco-2 Permeability: | -4.685 | MDCK Permeability: | 0.00001620 |
Pgp-inhibitor: | 0.049 | Pgp-substrate: | 0.001 |
Human Intestinal Absorption (HIA): | 0.007 | 20% Bioavailability (F20%): | 0.347 |
30% Bioavailability (F30%): | 0.249 |
Blood-Brain-Barrier Penetration (BBB): | 0.98 | Plasma Protein Binding (PPB): | 78.21% |
Volume Distribution (VD): | 2.435 | Fu: | 14.97% |
CYP1A2-inhibitor: | 0.96 | CYP1A2-substrate: | 0.544 |
CYP2C19-inhibitor: | 0.948 | CYP2C19-substrate: | 0.547 |
CYP2C9-inhibitor: | 0.862 | CYP2C9-substrate: | 0.03 |
CYP2D6-inhibitor: | 0.899 | CYP2D6-substrate: | 0.026 |
CYP3A4-inhibitor: | 0.96 | CYP3A4-substrate: | 0.481 |
Clearance (CL): | 5.936 | Half-life (T1/2): | 0.051 |
hERG Blockers: | 0.012 | Human Hepatotoxicity (H-HT): | 0.927 |
Drug-inuced Liver Injury (DILI): | 0.698 | AMES Toxicity: | 0.087 |
Rat Oral Acute Toxicity: | 0.915 | Maximum Recommended Daily Dose: | 0.879 |
Skin Sensitization: | 0.953 | Carcinogencity: | 0.846 |
Eye Corrosion: | 0.112 | Eye Irritation: | 0.088 |
Respiratory Toxicity: | 0.981 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC002611 | 0.816 | D0E9KA | 0.203 | ||||
ENC002612 | 0.630 | D0C1SF | 0.202 | ||||
ENC002525 | 0.608 | D04KTZ | 0.189 | ||||
ENC002532 | 0.574 | D0R2KJ | 0.187 | ||||
ENC002533 | 0.558 | D0Q2AT | 0.187 | ||||
ENC002529 | 0.554 | D0WY9N | 0.186 | ||||
ENC002778 | 0.520 | D0O6KE | 0.183 | ||||
ENC002610 | 0.520 | D02GAC | 0.181 | ||||
ENC005878 | 0.505 | D0R6RC | 0.180 | ||||
ENC005844 | 0.505 | D0WN0U | 0.179 |